Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Results>JD HEALTH 3Q Non-IFRS Operating Income Up ~60% YoY
Recommend 5 Positive 14 Negative 2 |
||||
|
||||
|
JD HEALTH (06618.HK) announced its third-quarter results for the period ending September 30, 2025, with revenue of RMB17.12 billion, up 28.7% YoY. Non-IFRS operating income was RMB1.378 billion, up 59.9% YoY. Non-IFRS profit grew 42.4% to RMB1.902 billion. During the third quarter of 2025, JD Health entered into strategic cooperation agreements with leading pharmaceutical companies, including Eli Lilly, Innovent Biologics, Eisai China, and Bayer China. The Company also debuted a range of innovative drugs online. In September 2025, JD Health partnered with several medical device brands, including Yuwell, Sinocare, and MicroTech, to establish the intelligent interconnected ecosystem alliance. The alliance aims to build a smart blood glucose management system. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
